Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... SAN DIEGO , May 24, 2013 ... a  company using proprietary taste science technologies to discover, ... David Linemeyer , Ph.D., the Company,s ... , Vice President, Investor Relations & Corporate Communications, will ... Friday, May 31, at 10:25 a.m. Eastern Time (7:25 ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Many factors ... and uptake or efflux transporters at the blood-tissue barrier. ... related to unbound fractions in the tissue rather than ... these disposition challenges is required to guide lead optimization, ... identify any species-dependent variables that may impact the likely ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)... 2013 Die Übersetzungen wurden von ... Bei der englischen Version handelt es sich ... der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren Zustand ... [*] -Definition [1] als kontrolliert gelten können ... einer von vier Denkweisen zugeordnet werden können, die alle ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Israel, Nov. 29 Protalix,BioTherapeutics, Inc. (Amex: PLX ... the close of business on December 24, 2007, as ... and to vote at, the,Company,s 2007 Annual Meeting of ... Meeting of Shareholders will be held on,January 31, 2008, ...
... the treatment ... disease ... Symbol: RVX, CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... of the very prestigious,Technology Pioneer Award in recognition of its NexVas(TM) Plaque Removal,program. ...
... Jerusalem Global Ventures today,announced that it will soon ... fund. The Fund will invest in private Israeli related,technology ... three years and,have a proven business model. First closing ... who founded Jerusalem Global in 1994, notes that,"Unlike the ...
Cached Biology Technology:Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 2Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 3Resverlogix Honoured with World Economic Forum Technology Pioneer Award 2Resverlogix Honoured with World Economic Forum Technology Pioneer Award 3Resverlogix Honoured with World Economic Forum Technology Pioneer Award 4Resverlogix Honoured with World Economic Forum Technology Pioneer Award 5Jerusalem Global Ventures Announces $200 Million Growth Equity Fund 2
(Date:5/23/2013)... with autologous cord blood. Following a cardiac arrest with ... been in a persistent vegetative state with minimal ... the cord blood containing stem cells, the symptoms improved ... speak simple sentences and to move. "Our findings, along ... doubts about the effectiveness of the new therapy", says ...
(Date:5/22/2013)... NEW YORK CITY, May 22, 2013 U.S. Forest ... multi-disciplinary team that, with funding from the TKF Foundation, ... spaces help communities and individuals recover from tragedy. , ... is one of six projects selected for grant funding. ... spaces and sacred spaces in recovery and resiliency, the ...
(Date:5/22/2013)... 22, 2013)The omega 3 fatty acids in fish oil ... much so that the American Heart Association currently recommends ... particularly fatty varieties rich in omega 3s. However, the ... In a new study, scientists led by Jason R. ... phenomenon by providing evidence that fish oil might specifically ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Fish oil may help the heart beat mental stress 2
... and US scientists has found there has been a massive ... the coast of Antarctica.,Comparing detailed measurements taken during the Australian ... data dating back to 1970, scientists estimate there has been ... volume of Antarctic Bottom Water, the cold dense water that ...
... IMPACT World+, the first worldwide regionalized life cycle impact ... during the 6th SETAC World Congress / SETAC Europe ... this innovative undertaking spearheaded by a team of leading ... production and consumption of goods and services generate significant ...
... able to target and destroy triple negative breast cancer, ... access journal Breast Cancer Research . Researchers from ... was able to destroy breast cancer cells and reduce ... cancers are found at diagnosis to be triple negative. ...
Cached Biology News:Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Launch of IMPACT World+ 2Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: